Reports
Sale
Global Dermatological Drugs Market Size, Trends, Report: By Diseases: Acne, Dermatitis, Psoriasis, Skin Cancer, Rosacea, Alopecia, Others; By Type: Prescription-based Drugs, Over-the-Counter Drugs; By Route of Administration: Topical Administration, Oral Administration, Others; By End User; Regional Analysis; Supplier Landscape: 2024-2032
Global Dermatological Drugs Market Outlook
The global dermatological drugs market size was valued at USD 22.59 billion in 2023, driven by the rising emphasis on improving physical appearance across the globe. The market is expected to grow at a CAGR of 11.3% during the forecast period of 2024-2032, with the values likely to rise from USD 25.1 billion in 2024 to USD 59.2 billion by 2032.
Dermatological Drugs: Introduction
Dermatological drugs are used to treat skin conditions and disorders, ranging from common acne to severe diseases like skin cancer and psoriasis. They are available in numerous forms like ointments, gels, creams and oral, or injectable formulations. These drugs may reduce inflammation, redness and itching, along with treating bacterial and fungal infections.
Global Dermatological Drugs Market Analysis
The growing prevalence of skin conditions and increasing drug approvals are among the key factors driving the dermatological drugs market growth in recent years. In July 2023, the FDA approved Verrica Pharmaceuticals Inc's Ycanth for treating a viral skin infection in adults as well as children aged above 2 years. Such approvals demonstrate that the dermatological drug development will continue in the forecast period as well.
With a rising focus on meeting the needs of patients suffering from untreatable dermatological conditions, pharmaceutical organizations are continuously growing and improving their business portfolios. In October 2023, DermBoint raised USD 35.2 million in Series B for dermatological therapies. The funds were dedicated towards Phase II trials for drug candidates treating seborrheic keratoses and melasma.
The growing convergence of artificial intelligence in drug development is one of the key factors aiding the growth of dermatological drugs market demand. With the ongoing trend, companies are collaborating and acquiring artificial intelligence enabled platforms for increasing their drug development potential. For instance, in November 2023, Almirall and Absci announced a dermatological drug discovery partnership worth USD 650 million, with the help of Absci’s artificial intelligence enabled drug creation platform.
Global Dermatological Drugs Market Segmentation
Market Breakup by Diseases
- Acne
- Dermatitis
- Psoriasis
- Skin Cancer
- Rosacea
- Alopecia
- Others
Market Breakup by Type
- Prescription-based Drugs
- Over-the-Counter Drugs
Market Breakup by Route of Administration
- Topical Administration
- Oral Administration
- Parenteral Administration
- Others
Market Breakup by End User
- Hospitals
- Homecare
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Dermatological Drugs Market Overview
The United States has been leading the dermatological drugs market share, which can be accredited to the high prevalence of skin conditions, a well-structured healthcare framework, and critical focus on research and development. Cosmetic dermatology is gaining prominence, with emphasis on cosmetic surgeries, anti-aging treatments, along with injectables, contributing to the market size.
In Europe, there is a growing trend for personalized medicine, which is fuelling the market growth in the region. With the existence of influential healthcare companies and academic institutions, there is rising development of biologic therapies. In addition, a significant portion of the geriatric population also demands better patient care. Government authorities have also been supporting market growth by setting up awareness campaigns on skincare.
Holding a substantial portion of the world’s population, the Asia Pacific region is experiencing high dermatological drugs market demand. Emerging economies like India and South Korea are witnessing improvements in the healthcare and research infrastructures to serve better treatment alternatives to patients. In addition, foreign companies are making noteworthy investments to leverage the academic talent and easy availability of resources pertaining to the area.
Global Dermatological Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- AbbVie Inc. (Allergan PLC)
- Amgen Inc.
- Galderma
- GlaxoSmithKline Plc.
- Leo Pharma
- Johnson & Johnson
- Novartis AG
- Organon International (Merck & Co. Inc.)
- Pfizer Inc.
- Sun Pharmaceutical Industries Limited
- Sanofi
- Bausch Health Companies Inc
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- AstraZeneca
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diseases |
|
| Breakup by Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Dermatological Drugs Market Overview
3.1 Global Dermatological Drugs Market Historical Value (2017-2023)
3.2 Global Dermatological Drugs Market Forecast Value (2024-2032)
4 Global Dermatological Drugs Market Landscape
4.1 Global Dermatological Drugs Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Dermatological Drugs Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Indication
4.2.3 Analysis by Route of Administration
5 Global Dermatological Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Dermatological Drugs Market Segmentation
6.1 Global Dermatological Drugs Market by Diseases
6.1.1 Market Overview
6.1.2 Acne
6.1.3 Dermatitis
6.1.4 Psoriasis
6.1.5 Skin Cancer
6.1.6 Rosacea
6.1.7 Alopecia
6.1.8 Others
6.2 Global Dermatological Drugs Market by Type
6.2.1 Market Overview
6.2.2 Prescription-based Drugs
6.2.3 Over-the-Counter Drugs
6.3 Global Dermatological Drugs Market by Route of Administration
6.3.1 Market Overview
6.3.2 Topical Administration
6.3.3 Oral Administration
6.3.4 Parenteral Administration
6.3.5 Others
6.4 Global Dermatological Drugs Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Homecare
6.5 Global Dermatological Drugs Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Dermatological Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Dermatological Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Dermatological Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Dermatological Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Dermatological Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 AbbVie Inc. (Allergan PLC).
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 Amgen Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 Galderma
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 GlaxoSmithKline Plc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Leo Pharma
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 Johnson & Johnson
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 Novartis AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 Organon International (Merck & Co. Inc.)
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 Pfizer Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Sun Pharmaceutical Industries Limited
17.10.1 Financial Analysis
17.10.1 Product Portfolio
17.10.2 Demographic Reach and Achievements
17.10.3 Mergers and Acquisition
17.10.4 Certifications
17.11 Sanofi
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 Bausch Health Companies Inc
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
17.13 Bristol-Myers Squibb Company
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisition
17.13.5 Certifications
17.14 F. Hoffmann-La Roche Ltd
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisition
17.14.5 Certifications
17.15 AstraZeneca
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisition
17.15.5 Certifications
18 Global Dermatological Drugs Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 22.59 billion in 2023, driven by growing focus on improving physical appearance across the globe.
The market is anticipated to grow at a CAGR of 11.3% during the forecast period of 2024-2032, likely to reach a market value of USD 59.2 billion by 2032.
The market demand is driven by the rising number of drug approvals to meet the demands of untreatable skin conditions.
The major market trends revolve around the increasing integration of artificial intelligence into the medical scenario, which has streamlined the process of novel drug development. In November 2023, Almirall and Absci announced a dermatological drug discovery partnership worth USD 650 million, which aimed to use Absci’s artificial intelligence enabled drug creation platform.
Based on diseases, the market is divided into acne, dermatitis, psoriasis, skin cancer, rosacea, and alopecia, among others.
The types of drugs include prescription-based drugs and over-the-counter drugs.
Major end users include hospitals and homecare.
The route of administration can be oral, parenteral, and topical among others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Key players involved in the market are AbbVie Inc. (Allergan PLC)., Amgen Inc., Galderma, GlaxoSmithKline Plc., Leo Pharma, Johnson & Johnson, Novartis AG, Organon International (Merck & Co. Inc.), Pfizer Inc., Sun Pharmaceutical Industries Limited, Sanofi, Bausch Health Companies Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd and AstraZeneca.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER